valid and that in most cases it would be destroyed and disappear with adequate drainage.
Dr Lees advised not draining collections of less than 50 ml (unless frank pus) or contaminated small collections. Haematomas and necrotic tissue should be drained.
Mr McCollum spoke of primary and secondary abscesses, e.g. in the liver from diverticulitis. Dr Freeney said that routine postoperative ultrasound would often find fluid collections. Dr Lees felt that in the operative field these were not significant. Mr Pollock felt strongly that all abscesses should be surgically tackled, repeatedly ifnecessary, to remove all necrotic material.
Early intervention was agreed to be of great value. There was discussion of the management of pancreatic fistulae; in difficult cases a radical distal pancreatectomy might be essential. Molecular biological perspectives in immunology Keywords: T-lymphocyte, leukaemia, oncogene, RFLP, HLA Molecular biology of T-lymphocyte activation Dr Mike Owen (ICRF, London) began his talk with an overview of the two main T-cell activation pathways. The first is initiated by antigen-MHC protein binding to the T-cell receptor-T3 complex, which can be mimicked by antibody against Tr (T-cell receptor) as well as T3, and by specific lectins. The second pathway is activated in the laboratory by anti-T1l antibody and with interleukin-4A, which is likely to be a natural ligand. Both types of T-cell activation can be assayed by measuring clonal proliferation and expression of interleukin-2 receptor. Discrete stages in T-cell activation are represented by sequential expression of surface antigens. At earlier stages, the interleukin-2 receptor is expressed, and interleukin-2 itself is secreted; later, large amounts of transferrin receptor appear on the cell surface. Finally, in the very late stages of activation, HLA class II antigens are expressed on the cell surface. Cloning strategies used to isolate cell-surface antigen genes have included:
(1) Cell-surface protein purification and amino acid sequence determination, leading to the synthesis of an oligonucleotide probe. The disadvantage of this approach is that cell-surface antigens are present in low concentrations. In the case of functional T-cell clones, more than 109 cells will generally be needed.
(2) Expression vectors such as bacteriophage lambda gtll can be screened with specific labelled antibody. The success of this method depends upon possessing an antibody which will recognize a feature common to both the natural and synthetic protein. Bacterial expression vectors have been used to clone the genes for T3 epsilon and gamma chains. (3) Eukaryotic transfection systems group have been used to clone T4, T8 and T9 (transferrin receptor) genes by introducing high molecular weight DNA into mouse L cells, andselectingforthe expressionofa particular surface antigen by fluorescence activated cell sorting. (4) Subtractive hybridization has been used to clone the T-cell receptor alpha, beta and gamma chain genes. Using this technique, one can clone genes coding for previously unknown proteins. One pitfall is the requirement for a very low level of transcriptional expression in the cell line used to prepare the mRNA; absence of the relevant cell surface antigen is not a guarantee of sufficiently low mRNA levels. (5) Cloning using bioassay is particularly useful with growth factor genes; translation ofmRNA inXenopus oocytes or Cos cells can be detected by bioassay.
Analysis of cloned sequences has revealed the primary structure of the T-cell receptor alpha and beta chains, which are divided into several domains: first, the leader sequence that inserts the polypeptide through the lipid bilayer; next, the V-region sequence of about 90 amino acids, then the independentlyassorting joining region domain, followed by an extracellular constant region. The polypeptide is joined into and through the lipid bilayer by.a transmembrane sequence of 26 amino acids, followed by a short cytoplasmic tail of4-5 amino acids.
Multiple germ line and J chain gene segments contribute to diversity because (in principle) any V-gene segment can combine with any J-gene segment via a D segment. Moreover, in the T-cell receptor, direct V to J joining is shown by cDNA cloning. V to D and D to Jjoining in the T-cell receptor can alsobe obtained. Somatic mutation can result from junctional flexibility, because the precise point ofjoining of the V to D and D to J gene segments can vary, creating local amino acid changes, whereas end region diversity may result from deoxynucleotidyl terminal transferase, which polymerizes nucleotides in a random fashion at 3' DNA termini. The D-gene segments can be read in all three reading frames generated as a result of the rearrangement process. The calculated diversity of the T-cell receptor is the same order of magnitude as the B-cell receptor, so that in theory the repertoire of the T-cell receptor is expected to be as large as that of the B-cell receptor.
The timing ofT-cell receptor gene rearrangement is such that beta-chain rearrangement occurs early in thymocyte ontogeny. Initially D-beta joins to J-beta, then a joining of V-beta to D-beta and J-beta gene segments forms the variable coding block. Alpha chain expression and rearrangement occurs later, and requires productive beta-chain rearrangement Expression of genes during thymocyte ontogeny can be analysed by Northern blotting analysis, and closed thymic organ culture can be used to preclude colonization of the thymus by T-cell immigrants during development. Immature (T3 negative) human thymocyte mRNA can be shown by this method to contain a high level of beta-chain, but low levels of alpha-chain transcripts. However, alpha-chain transcripts are present in mature (T3 positive) thymocytes, implying that alpha-chain genes are expressed late in thymocyte ontogeny.
The antigen T3, which is functionally and physically associated with the T-cell receptor at the cell surface, has been implicated very strongly in the process of signal transfer across the lipid bilayer consequent to antigen MHC recognition by the T-cell receptor. The T3 antigen itself comprises three polypeptide chains: gamma, delta, and epsilon. Comparison ofthe deduced amino acid sequence ofthe T3 gamma and delta genes reveals that there is about 70% homology between the intracellular regions of these genes. In contrast, the transmembrane and extracellular domains of these two genes show much less similarity.
Chromosomal translocations and human leukaemias Dr Terry Rabbits (MRC Laboratory of Molecular Biology, Cambridge) discussed the involvement of antigen receptors and chromosomal translocation in human leukaemias. Abnormal rearrangement of T-cell receptor genes (which occur in a number of B-and T-cell leukaemias) result in the juxtaposition of receptor genes either with cellular oncogenes or other gene segments. This linkage may activate a cellular oncogene, or fuse a T-cell receptor gene with an inappropriate gene sequence to form a chimaeric receptor.
The experimental basis of this research derives from the observation that most leukaemias and lymphomas have a chromosomal abnormality, such as a translocation, inversion, or an interstitial deletion. These abnormalities have end-points near the genes which undergo rearrangement in B-cells or T-cells (the immunoglobulin genes in B-cells and the T-cell receptor genes in T-cells). Individual tumour types tend to carry one or the other type of abnormality, suggesting that these abnormalities are related to the tumour's cause.
Cytogenetic evidence indicates that in Burkitt's lymphoma over 90% of tumours have a reciprocal translocation between the long arm of chromosome 8 (band q24), where the c-myc oncogene is located, and the long arn of chromosome 14 (band q32), site of the immunoglobulin heavy chain genes. In two variant Burkitt's lymphomas, each representing about 5% of Burkitt's cases, a similar breakpont near c-myc is associated with the immunoglobulin light chains (kappa or lambda). Some B-cell pro-lymphocytic leukaemias and B-cell follicular lymphomas contain translocations involving chromosome 14 (band q32) and presumably involve cellular oncogenes other than c-myc. C-myc messenger encodes for a nuclear protein of unknown function, which may be needed by the resting cell to enter the cell cycle.
In Burkitt's lymphoma the chromosomal breakpoint occurs upstream of the c-myc gene, whereas in the variants the breakpoint occurs downstream of the c-myc gene. Despite this apparent absence of positional effect, the main enhancer involved in the control of immunoglobulin transcription is interrupted in the vast majority of Burkitt's lymphoma 8-14 translocations, and moves onto the 8 q-chromosome; the enhancer is not responsible for activation of the c-myc gene in such cases. At the DNA sequence level, a wide variety of breakpoints can occur with respect to myc; some are quite near c-myc, whereas others may occur at least 100 kb distant. At present, there is no general explanation for c-myc activation, and a variety of mechanisms may exist.
In T-cell tumours, such as chronic lymphocytic leukaemias, two types of abnormality are observed: either an inversion of the long arm of chromosome 14 (breakpoints at band qll and q32) or an analogous translocation between homologous chromosomes, which involves the same breakpoints in chromosome 14. In some acute leukaemias, a translocation between chromosome 11 (band q13) and chromosome 14 (band qll) is observed. The breakpoint on chromosome 14 corresponds to the cytogenetic location of the T-cell receptor alpha-chains in humans.
In one cell line which had an inversion at chromosome 14, the junctions which represented the qll positions were cloned using a T-cell receptor alpha-chain hybridization probe. In this cell line there are two rearrangements, one in an upstream T-cell receptor J-segment, and one a downstream J-chain segment. A T-cell receptor variable alpha gene segment is joined to a J-alpha segment. In this position a normal (but non-productive) V-D-J process occurred which is not in the correct reading frame, and cannot produce protein. On the other chromosome, the junction ofthe inversion consists ofan immunoglobulin heavy chain variable segment, joined (probably) to a D-alpha J-alpha gene, resulting in an immunoglobulin-T-cell receptor fusion.
The lack of adequate anti-constant region T-cell receptor antibodies has prevented the presence ofthe chimaeric protein on the cell surface to be directly demonstrated; again, the chimaeric IgT receptor could be expressed at a low level. However, it is likely that IgT may be present at the cell surface. A 1.6 kbase mRNA corresponding to IgT mRNA can be detected in T-cells with a probe containing the immunoglobulin VH region joined to the IgT region, as well as with T-cell receptor alpha probe. The level of IgT mRNA hybridized to the T-cell receptor probe in the chimaeric cells is about one-tenth that in the control cell line, perhaps because the IgT gene is under the control of an immunoglobulin promoter of inappropriate tissue specificity. T-cell receptor beta-chain mRNA is also found. mRNA coding for the closely associated T3 protein can also be demonstrated in the T-cell, and fluorescence-activated cell sorting indicates that these cells are approximately 20% as positive for T3 protein as cells which express normal receptor.
Autotriggering by a chimaeric receptor is a possible explanation for uncontrolled antigen-independent cell proliferation observed in the T-cell chronic lymphocytic leukaemias. It is possible that the VH gene segment present in the chimaeric receptor could cause the receptor to fold in a way which mimics antigen recognition, resulting in the proliferation and survival of the T-cell clone as a pre-leukaemic cell over a number ofyears. This survival may provide the opportunity for subsequent events to occur within the pre-leukaemic cell (such as oncogene activation) to create the overtly malignant T-cell tumour.
Restriction length polymorphisms and diseases mapping on the X-chromosome Dr Susan Malcolm (Clinical Genetics and Institute of Child Health, London) addressed the meeting on the topic of gene tracking and X-linked disease.
Among the many inherited diseases which map to the X-chromosome are several immune deficiency diseases; for most of these diseases, the protein involved is not known, so mapping is done by linkage analysis between a restriction fragment length polymorphism (RFLP) and a disease locus by observing the pattern of inheritance in pedigrees.
The X-linked diseases are suitable for this approach because the X-chromosome can be completely covered with adjacent linked fragments representing RFLPs. Moreover, the presence of the polymorphism can be correlated with the disease in males, where a single X-chromosome is present. A number of autosomal dominant diseases such as Huntington's chorea and autosomal recessive genes, such as cystic fibrosis, have also been studied in this way.
Prenatal diagnosis of sickle cell anaemia is facilitated by the mutation in the sickle cell allele which results in a RFLP. Diseases on the X-chromosome for which a tightly linked RFLP have been described include haemophilia A, for which there is also a gene-specific probe (Factor VIII gene), Duchenne muscular dystrophy, Norries disease, the eye disease retinosis pigmentosa, ectodermal dysplasia, and choroideraemia. Agammablobulinaemia is the latest disease to be added to the list; close linkage (theta = 0.04, LOD 3.65) has been reported between this locus and two probes on the long arm ofthe X-chromosome. The theta value represents the fraction of cases in which recombination is observed between the disease locus and the locus defined by a particular probe. The LOD (logarithm of the odds) score is a statistical measure of the evidence in favour of linkage. A LOD score greater than 3 means that the odds are better than a thousand to one that two loci are linked, and is considered to be good experimental evidence for the purpose of prenatal diagnosis. However, if there are two types of the disease, they need not map to the same region.
RFLPs are detected by Southern blot analysis of DNA digested with a restriction endonuclease, and visualized by hybridization with an appropriate DNA probe. Between the DNA from any two randomly selected individuals, about one base in 100 is polymorphic, so RFLPs are plentiful.
As a RFLP associated with a disease is often located some distance along the chromosome away from the gene responsible for the disorder, a quantitative measure of linkage is assigned to the RFLP. The genetic distance in centimorgans is related to recombination frequency such that for two markers 5 centimorgans apart, the two markers will be coinherited in 95% of cases. In most regions of the genome a centimorgan corresponds to about a million base pairs; the X-chromosome is about 185 centimorgans long.
Three approaches to the search for probes to Xlinked diseases were described: (1) The random approach. (2) An approach which utilizes 'unusual cases' of the disease (used in Duchenne muscular dystrophy). Occasionally in X-linked diseases, a girl will be found to be affected. In some cases this is due to a translocation between the X-chromosome and an autosome. In the case of Duchenne muscular dystrophy, an X-21 translocation was observed, and the normal X-chromosome will be preferentially inactivated. In this instance the ribosomal genes on chromosome 21 have made it possible to isolate a clone including the chromosomal breakpoint. A more direct approach exploited in Duchenne muscular dystrophy depends on the identification of a deletion on the X-chromosome and isolation of deleted sequences by subtractive hybridization.
The defect in chronic granulomatous disease (CGD) is known to be a cytochrome gene defect, and the map locaton has been determined from the data of a small number ofboys who have Duchenne muscular dystrophy. These boys have also inherited CGD, and for them Duchenne muscular dystrophy has arisen from a deletion or rearrangement on the short arm of their X-chromosome simultaneously affecting the CGD locus. Coinheritance of CGD with Duchenne muscular dystrophy allows the approximate mapping of CGD to the region of the X-chromosome involved in muscular dystrophy.
Some preliminary results concerning severe combined immunodeficiency (SCID) from one very large pedigree containing five informative meioses were described in which no crossing over between probe 19-2 and the disease locus were observed. Similarly, in a small number ofmeioses in families with WiskottAldrich, thus far no crossing-over has been observed with 19-2 (and another probe, S-21). So it seems a definite possibility that the diseases may be clustered in a relatively small region ofthe X-chromosome near the locus defined by probes 19-2 and S-21.
Dr Malcolm related a case involving a mildly mentally retarded boy who also has the eye disease choroideraemia. This patient has a deletion of the X-chromosome (which is the cause of the choroideraemia) including the locus of the 19-2 probe and the pdp-34 probe. No impairment of immune function is evident, further narrowing the agammaglobulinaemia region of the X-chromosome to within 10 to 15 centimorgans.
For all these diseases, the objective is to understand the genetic nature of the disease, and to produce cDNA probes that map in the affected gene. Information ofthis nature has already proven invaluable in genetic counselling and prenatal diagnosis. Eventually, expression of the gene and the function of the protein products might be discovered, leading to an understanding of the disease at the molecular level.
Molecular organization of human leukocyte
antigen genes Dr John Trowsdale (Imperial Cancer Research Fund, London) spoke on the genetic analysis of the human HLA region. The known function of the HLA genes is to present antigen to T-cells; by studying HLA products by means of DNA clones one can learn something about the mechanism of presentation of antigens to T-cells and to T-cell receptor molecules.
One of the features of the HLA system is the polymorphism characteristic of these genes. Certain diseases are associated with these genes; for instance, arthritis, diabetes, and narcolepsy, which has a very strong association with DR2. The HLA genes are an example of a multigene family, such that any alpha or beta-chain probe can cross-hybridize with other members of the alpha or beta families. However, members ofthe complete supergene family (including the T-cell receptor and immunoglobulins) are more distantly related, and cannot be isolated using HLA probes.
Class I HLA antigens are encoded by a single alpha chain (44 000 MW) for the A,B or C products. Coupled with these chains is the beta-2 microglobulin, located on chromosome 15. Telomeric to this region are a large number of related genes (around 30 in the mouse), which are closely related to the A, B and C HLA products, but do not appear to have a role as major expressed proteins in most cells. Class II antigens are known to be encoded on chromosome 6, and include DP, DQ, DR, DX and DZ genes.
The structures of class I and class II antigens are similar, as each of these molecules consists of four extracellular protein domains. In the case of class I they are alpha-1, alpha-2 and alpha-3 domains external to the cell membrane; the fourth domain is represented by beta-2 microglobulin which is noncovalently bound to the alpha-chain. In the class II products the beta-1 and beta-2 domains are encoded by the beta-chain, and alpha-1 and alpha-2 domains are encoded by the alpha-chain. The alpha-3 beta-2 microglobulin domains, and beta-2 and alpha-2 domains, in the case ofclass II HLA proteins, all have similarities with immunoglobulin and T-cell receptor domains. In particular, the position of the cysteines involved in the disulfide bonds are absolutely conserved in all these proteins. The polymorphism on these molecules resides on the domains which are outside the cell membrane.
The HLA class II gene family has been mapped by screening genomic cosmid clones with a DR alpha cDNA probe. A number of closely related sequences were identified, including DQ alpha and the closely related DX alpha, two genes which correspond to the protein sequence of DP alpha (DP alpha 1 and 2), and a gene called DZ alpha. There are at least six nonallelic alpha chain genes, all having characteristic restriction fragment lengths. The genes were localized to chromosome 6 by Southern blot analysis using a somatic cell hybrid containing the mouse background of chromosomes and a single human chromosome containing part of chromosome 6 including the HLA region.
Despite the complexity ofthe region, an underlying pattern is apparent and one can infer from sequence data that an initial pair ofalpha and beta-chain genes were duplicated at least six times, some duplications occurring at different times in the evolution of the region. Seen in this light, there is a strong analogy to be made with the organization of the mouse MHC region. A number of laboratories have assembled the cosmid clones into a linear map by identifying overlapping regions into a working map of the HLA-D region. The DP-alpha gene is closely linked to the DP-beta gene (DP-alpha-1 and DP-beta-1 are the expressed genes, whereas DP-alpha-2 and DP-beta-2 are pseudogenes). The DZ-alpha gene and DO-beta are potentially expressed, but have no known function; DX-beta and DX-alpha are closely related to the expressed genes DQ-alpha and beta, but so far no function or expression of these genes has been described, although these are not pseudogenes. DQalpha and DQ-beta correspond to the expressed genes known as the DQ product. The DR region has one or two expressed beta genes. One of these beta genes combines with the alpha gene to give the normal serologically detected DR product DR1, DR2, DR3, etc.
Another DR-beta gene gives rise to other DR-related products, DR52 and DR53. It is believed that these DR-beta genes can combine with the same DR-alpha gene product.
Pulse field electrophoresis, a new technique for resolving large restriction fragments, has allowed more precise mapping of the HLA region. This new map shows that DZ-alpha is separated by about 350,000 bp from DO-beta, suggesting that there may be more class II regions in this gap.
The DZ-alpha gene is a typical class II alpha gene, except that the poly A sequence is ACTAAA (rather than the more common AATAAA), suggesting that polyadenylation is different in this gene. The transcript for the DZ-alpha gene is 3.5 kb, compared with DP-beta which is 1.3 kb.
The typical structure of an alpha-chain gene (DRalpha), and of a beta-chain gene (DP-beta), reveals that the genes are organized as exons, with long introns in between. The exons correspond more or less to the protein domains; there is a separate exon for the beta-1 domain and for beta-2 domains. The alpha-1 domain of the DQ region of three different individuals shows considerable amount of variation in this domain but only a few conservative changes in the second domain. In contrast, DP-alpha has only one or two amino acid variations, and DR-alpha is almost entirely constant between individuals. DQalpha shows considerable variation in the alpha 1 domain, and conservative changes in the second domain, whereas DP-alpha shows several changes scattered throughout the chain. This might suggest some functional distinction between DP, DQ and DR which would explain the disparity in extent of variation between individuals. Beta-chain sequences are all variable, but DP shows somewhat less variation than DQ and DR.
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